EnteroMedics Presses Towards Approval, Rollout Of Novel Obesity Device
This article was originally published in The Gray Sheet
Executive Summary
During an April 30 earnings call, EnteroMedics Inc. discussed its plans for securing a PMA for its Maestro neuromodulation device targeting obese patients, and subsequent rollout, in advance of an FDA panel meeting.